Body: 

Innate Pharma presented new data at the AACR Annual Meeting, April 14-18, in Chicago, including preliminary data suggesting promising anti-tumor activity of the combination of monalizumab and cetuximab in patients with platinum pretreated SCCHN.

Order: 
2